Inhibrx

In a strategic move to bolster its rare disease business, Sanofi SA (NASDAQ:SNY) has agreed to acquire the drug development project INBRX-101 from its parent company, Inhibrx Inc (NASDAQ:INBX). This acquisition is valued at approximately $2.2 billion. What Happened: The French healthcare company...

Insider buying can be an encouraging signal for potential investors during periods of uncertainty. A number of executives and other insiders returned to the buy window last week. A beneficial investor added to its stake after an initial public offering. Conventional wisdom says that insiders and...